IT201700109459A1 - METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE - Google Patents

METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE

Info

Publication number
IT201700109459A1
IT201700109459A1 IT102017000109459A IT201700109459A IT201700109459A1 IT 201700109459 A1 IT201700109459 A1 IT 201700109459A1 IT 102017000109459 A IT102017000109459 A IT 102017000109459A IT 201700109459 A IT201700109459 A IT 201700109459A IT 201700109459 A1 IT201700109459 A1 IT 201700109459A1
Authority
IT
Italy
Prior art keywords
kits
breast cancer
prognosis
perform
perform prognosis
Prior art date
Application number
IT102017000109459A
Other languages
Italian (it)
Inventor
Antonio Rulli
Angelo Sidoni
Original Assignee
Univ Degli Studi Di Perugia
Lega Italiana Per La Lotta Contro I Tumori Lilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Di Perugia, Lega Italiana Per La Lotta Contro I Tumori Lilt filed Critical Univ Degli Studi Di Perugia
Priority to IT102017000109459A priority Critical patent/IT201700109459A1/en
Publication of IT201700109459A1 publication Critical patent/IT201700109459A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
IT102017000109459A 2017-09-29 2017-09-29 METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE IT201700109459A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102017000109459A IT201700109459A1 (en) 2017-09-29 2017-09-29 METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000109459A IT201700109459A1 (en) 2017-09-29 2017-09-29 METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE

Publications (1)

Publication Number Publication Date
IT201700109459A1 true IT201700109459A1 (en) 2019-03-29

Family

ID=61024941

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000109459A IT201700109459A1 (en) 2017-09-29 2017-09-29 METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE

Country Status (1)

Country Link
IT (1) IT201700109459A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100023900A1 (en) 2021-09-16 2023-03-16 Univ Degli Studi Di Perugia METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
WO2009158143A1 (en) * 2008-05-30 2009-12-30 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
EP2298936A1 (en) * 2008-07-02 2011-03-23 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas (C.I.E.M.A.T.) Genomic fingerprint of mammary cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
WO2009158143A1 (en) * 2008-05-30 2009-12-30 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
EP2298936A1 (en) * 2008-07-02 2011-03-23 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas (C.I.E.M.A.T.) Genomic fingerprint of mammary cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J PANSE ET AL: "Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients", BRITISH JOURNAL OF CANCER, vol. 99, no. 6, 16 September 2008 (2008-09-16), pages 930 - 938, XP055061916, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6604621 *
KATHERINE E. VARLEY ET AL: "Recurrent read-through fusion transcripts in breast cancer", BREAST CANCER RESEARCH AND TREATMENT., vol. 146, no. 2, 15 June 2014 (2014-06-15), US, pages 287 - 297, XP055457370, ISSN: 0167-6806, DOI: 10.1007/s10549-014-3019-2 *
VALENTINA MIANO ET AL: "Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer", ONCOTARGET, vol. 7, no. 3, 19 January 2016 (2016-01-19), XP055457171, DOI: 10.18632/oncotarget.6420 *
YASHAR S. NIKNAFS ET AL: "The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression", NATURE COMMUNICATIONS, vol. 7, 26 September 2016 (2016-09-26), pages 12791, XP055457168, DOI: 10.1038/ncomms12791 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100023900A1 (en) 2021-09-16 2023-03-16 Univ Degli Studi Di Perugia METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER
WO2023041544A1 (en) 2021-09-16 2023-03-23 Università degli Studi di Perugia Method for the diagnosis and prognosis of tumours

Similar Documents

Publication Publication Date Title
CO2019001980A2 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
CO2017004516A2 (en) Humanized anti-ox40 antibodies
CL2018002782A1 (en) Modified dressing
EA202091540A1 (en) ANTIBODIES TO LILRB2
EP3707158A4 (en) Cancer biomarkers and methods of use thereof
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
BR112018003269A2 (en) anti-dll3 drug-antibody conjugates and methods of use
BR112017017700A2 (en) cancer treatment methods, compositions and kits
IL287607A (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
BR112016017112A2 (en) APILIMOD COMPOSITIONS AND METHODS OF USE THEREOF
CL2018001139A1 (en) Anti-htra1 antibodies and methods of use thereof.
BR112018010279A2 (en) new anti-emr2 antibodies and methods of use
BR112017004444A2 (en) new anti-mfi2 antibodies and methods of use
BR112016027043A2 (en) Combination, pharmaceutical composition comprising glucocorticoid and edo-s101, kit and use in cancer treatment
EA201791391A1 (en) METHODS OF OBTAINING DIARYLTIOHYDANTOIN COMPOUND
DK3253800T3 (en) Prostate antigen standards and use thereof
MA47811A (en) KIT INCLUDING AN ANTIBODY-DRUG IGF-1R CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
MX2016015163A (en) Mit biomarkers and methods using the same.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
IT201700052359A1 (en) METHOD FOR THE REVELATION OF THE PRESENCE OF MERCURY IN WATER AND KIT FOR THE REALIZATION OF THE METHOD
WO2015153997A3 (en) Notch3 antibodies and uses thereof
BR112018012884A2 (en) new anti-mmp16 antibodies and methods of use
DK3577237T3 (en) METHOD FOR INDICATING THE PRESENCE OR ABSENCE OF PROSTATE CANCER IN INDIVIDUALS WITH SPECIFIC CHARACTERISTICS
IT201700109459A1 (en) METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer